Early versus conventional treatment for patent ductus arteriosus in preterm infants

Am J Perinatol. 2013 Apr;30(4):289-95. doi: 10.1055/s-0032-1324696. Epub 2012 Aug 23.

Abstract

Objective: After the introduction of a new protocol based on the early treatment with indomethacin for patent ductus arteriosus, the objective of this study was to assess the safety and efficacy of this new practice in comparison with the safety and efficacy of the conventional treatment in a high-risk population.

Study design: We conducted a retrospective cohort study including 154 newborns with an average gestational age of 26.4 weeks (1.37 standard deviation) and an average birth weight of 855 g (201.5 standard deviation). A statistically descriptive analysis was performed with SPSS Statistics Pack version 17.0.

Results and conclusions: We did not find any statistically significant differences in the clinical features of the two treatment groups, nor in the main efficacy, morbidity, and mortality results.

Publication types

  • Comparative Study

MeSH terms

  • Cardiovascular Agents / therapeutic use*
  • Chi-Square Distribution
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Ductus Arteriosus, Patent / diagnostic imaging
  • Ductus Arteriosus, Patent / drug therapy*
  • Ductus Arteriosus, Patent / mortality
  • Echocardiography, Doppler
  • Female
  • Follow-Up Studies
  • Gestational Age
  • Humans
  • Indomethacin / therapeutic use*
  • Infant, Newborn
  • Infant, Premature*
  • Male
  • Retrospective Studies
  • Risk Assessment
  • Survival Rate
  • Time Factors
  • Treatment Outcome

Substances

  • Cardiovascular Agents
  • Indomethacin